Latest Daily News

Latest News
June 6, 2017

Dr. Druker, who was instrumental in the development of imatinib, highlighted the hurdles he faced in bringing the tyrosine-kinase inhibitor to market, particularly the skepticism from others in the field who were sure that a single-agent therapy for cancer would never work.

Read more
June 6, 2017

Carl H. June, MD, of the University of Pennsylvania, accepted the 2017 David A. Karnofsky Memorial Award and Lecture on June 3, an honor bestowed for his pioneering work on engineering T cells in targeted cancer therapy.

Read more

June 6, 2017

Researchers presented results of four studies evaluating new approaches to targeted therapies for patients with lung cancer, including metastatic non–small cell lung cancer.

Read more
June 6, 2017

In contrast to more common cancers, some sarcoma subsets are fairly rare and standard treatments have not been established. However, for each sarcoma type discussed, strategies are being developed with the aim of improving outcomes for patients with sarcoma.

Read more

June 5, 2017

Pertuzumab improved invasive disease–free survival (IDFS) in patients with HER2-positive, early-stage breast cancer when added to chemotherapy and trastuzumab.

Read more
June 5, 2017

Both nivolumab alone and in combination with ipilimumab resulted in a promising disease control rate in patients with relapsing malignant pleural mesothelioma (MPM), according to the results of Abstract LBA8507.

Read more
June 5, 2017

The EGFR tyrosine-kinase inhibitor gefitinib appears to offer a disease-free survival benefit over vinorelbine/cisplatin as adjuvant therapy in patients with non–small cell lung cancer with EGFR-activating mutation.

Read more
June 5, 2017

Results from two separate trials suggest that lenalidomide can induce deeper and longer remission in patients with multiple myeloma when used as part of induction and maintenance therapy.

Read more
June 5, 2017

The PD-L1 inhibitor pembrolizumab continued to demonstrate an overall survival benefit compared with chemotherapy among patients with advanced urothelial cancer with no new safety signals.

Read more
June 5, 2017

The safety and efficacy of trastuzumab biosimilars for neoadjuvant breast cancer therapy demonstrated comparable safety and efficacy, according to two studies.

Read more
June 5, 2017

Results from the Short-HER study suggest a shorter course may reduce the rate of severe cardiac toxicity.

Read more
June 4, 2017

Although new discoveries regarding the biology of sarcoma are occurring at a historic pace, novel drug development in this rare cancer is complicated by the heterogeneous nature of disease.

Read more

June 4, 2017

ASCO’s recommendations and criteria to improve the development, implementation, and analysis of oncology pathways are first steps in managing enhancements to patient care while proving their benefit at the patient and societal levels.

Read more
June 4, 2017

Multiple studies have found that people age 65 and older are underrepresented in both cancer registration trials and the National Cancer Institute’s National Clinical Trials Network (NCTN) clinical trials, with only modest improvement over time.

Read more
June 4, 2017

Here are some bite-sized articles from Monday's ASCO Daily News coverage.

Read more
June 4, 2017

The use of a web-based system that allowed patients to report symptoms to their clinicians remotely was associated with benefits including improved quality of life and longer overall survival.

Read more
June 4, 2017

CENTRA will serve as a hub for ASCO’s data, research, and related analyses.

Read more
June 4, 2017

Patients with stage III endometrial cancer experienced an 11% FFS benefit with the combination treatment compared with those who received radiotherapy alone.

Read more

June 4, 2017

Data from two phase II studies, the CheckMate 204 trial and the Anti-PD1 Brain Collaboration trial, lend support to combined use of nivolumab and ipilimumab to yield responses in melanoma that has metastasized to the brain.

Read more

June 4, 2017

Olaparib tablet monotherapy yielded improved progression-free survival compared with standard-of-care chemotherapy among women with HER2-negative metastatic breast cancer and a germline BRCA mutation.

Read more